 Advaxis, Inc. NASDAQ: ADXS, CEO Ken Berlin presented at the Benzinga Biotech Small-Cap Conference on March 24, 2021. Advaxis, Inc., a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, is making new waves as it takes definitive steps to prove that the company is no longer your grandfathers Advaxis, according to company CEO Ken Berlin. 